Immunotherapy has been extensively explored in recent years with encouraging results in
selected types of cancer. Such success aroused interest in the expansion of such …

Oncolytic viruses possess the ability to infect, replicate and lyse malignantly transformed
tumour cells. This oncolytic activity amplifies the therapeutic advantage and induces a form …

New immuno-oncology therapies are improving cancer treatments beyond the former
standard of care, as evidenced by the recent and continuing clinical approvals for …

Cancer Immunotherapy relies on harnessing a patient's immune system to fine-tune specific
anti-tumor responses and ultimately eradicate cancer. Among diverse therapeutic …

Recent advances in cancer immunotherapy have renewed interest in oncolytic viruses (OVs)
as a synergistic platform for the development of novel antitumor strategies. Cancer cells …

The concept of oncolytic virus (OV)-mediated cancer therapy has been shifted from an
operational virotherapy paradigm to an immunotherapy. OVs often induce immunogenic cell …

For the past 150 years cancer immunotherapy has been largely a theoretical hope that
recently has begun to show potential as a highly impactful treatment for various cancers. In …

Highlights•Oncolytic viruses (OVs) can modulate tumour microenvironment (TME) towards
less immunosuppressive phenotype and induce anti-cancer immunity.•OVs can be used as …

Despite the fact that the new drugs and targeted therapies have been approved for cancer
therapy during the past 30 years, the majority of cancer types are still remain challenging to …

Oncolytic viruses can be usefully integrated into tumour immunotherapies, as they target
multiple steps within the cancer–immunity cycle. Oncolytic viruses directly lyse tumour cells …